Dissecting the Decision: Investigators Discuss the Available Data and Clinical Factors That Shape the Management of Gastrointestinal Cancers new

Interview with Johanna C Bendell, MD

Track 1: Perioperative systemic therapy options for patients with pan-RAS wild-type colon cancer and a solitary, operable hepatic metastasis
Track 2: Primary tumor sidedness as a predictive marker for EGFR antibodies in first- and later-line settings
Track 3: Biologic rationale for differences between left- and right-sided primary colon cancers
Track 4: Sequencing TAS-102 and regorafenib in patients with refractory, metastatic colorectal cancer (mCRC)
Track 5: Neutropenia as a correlate of treatment response in patients with mCRC treated with TAS-102
Track 6: Initial dosing and dose modifications with regorafenib in mCRC
Track 7: FOLFOXIRI/bevacizumab as initial treatment for BRAF-mutant mCRC
Track 8: Triplet combination regimen with BRAF/MEK/EGFR inhibitors for BRAF-mutant mCRC
Track 9: Clinical evidence for the use of doublet regimens — trastuzumab/lapatinib or trastuzumab/pertuzumab — for HER2-amplified mCRC
Track 10: Microsatellite instability (MSI), increased mutational burden and response to anti-PD-1/anti-PD-L1 checkpoint inhibitors
Track 11: Use of anti-PD-1/anti-PD-L1 antibodies versus chemotherapy/biologic regimens as first-line therapy for mCRC
Track 12: Implication of immune-related adverse events on long-term treatment with anti-PD-1/anti-PD-L1 checkpoint inhibitors
Track 13: MSI testing in other solid tumors
Track 14: Anti-PD-1/anti-PD-L1 antibodies alone or in combination with chemotherapy for patients with colon cancer and potentially resectable liver metastases
Track 15: Biologic rationale for the combination of anti-PD-L1 antibodies and MEK inhibitors in microsatellite-stable mCRC
Track 16: Clinical strategies to enhance response to anti-PD-1/anti-PD-L1 checkpoint inhibitors in ongoing clinical trials

Interview with Bert H O’Neil, MD

Track 1: Selection of adjuvant chemotherapy for patients with pancreatic cancer
Track 2: Choice of neoadjuvant chemotherapy regimen — FOLFIRINOX versus nab paclitaxel/gemcitabine — for pancreatic adenocarcinoma
Track 3: Activity and tolerability of nanoliposomal irinotecan (nal-IRI; MM-398) with 5-FU/LV as second-line therapy for metastatic pancreatic cancer
Track 4: Mechanism of action of the recombinant human hyaluronidase enzyme PEGPH20 in pancreatic cancer
Track 5: Ramucirumab alone or with paclitaxel as second-line therapy for metastatic HER2-negative gastric cancer
Track 6: Effectiveness of nivolumab as salvage treatment after second- or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer
Track 7: Activity and tolerability of the cancer stemness inhibitor napabucasin (BBI608) in combination with chemotherapy for advanced gastric cancer and other solid tumors
Track 8: Initial dosing and dose modifications with sorafenib for patients with hepatocellular carcinoma (HCC) with Child-Pugh A cirrhosis
Track 9: Sequencing regorafenib and checkpoint inhibitors as second-line therapy in advanced HCC
Track 10: Results of the Phase III RESORCE trial: Regorafenib for patients with HCC and disease progression on sorafenib
Track 11: Activity and duration of response with nivolumab in advanced HCC
Track 12: Investigation of immune checkpoint inhibitor-based combination therapies for patients with advanced HCC
Johanna C Bendell, MD
Director, GI Oncology Research
Associate Director
Drug Development Unit
Sarah Cannon Research Institute
Nashville, Tennessee
Bert H O’Neil, MD
Professor of Medicine
Director, Phase I and GI Malignancies Programs
Indiana University Simon
Cancer Center
Indianapolis, Indiana
Neil Love, MD
Research To Practice
Miami, Florida